Prostate Cell News Volume 8.46 | Dec 1 2017

TOP STORY

Cell Death Linked to Tumor Growth in Prostate Cancer Patients

The goal of any cancer treatment is to kill tumor cells. Yet, one little understood paradox of certain cancers is that the body’s natural process for removing dead and dying cells can actually fuel tumor growth. A new study identifies the pathway by which this poorly understood action occurs in metastatic prostate cancer cells. [Press release from University of Michigan discussing online prepublication in J Clin Invest] Press Release | Full Article

(Ranked by impact factor of the journal)

PPARδ Elicits Ligand-Independent Repression of Trefoil Factor Family to Limit Prostate Cancer Growth

The authors provided evidence of tumor suppressive activity of PPAR-β/δ (PPARD) in prostate cancer through a non-canonical and ligand-independent pathway. PPARD was downregulated in prostate cancer specimens. In murine prostate epithelium, PPARD gene deletion resulted in increased cellularity. [Cancer Res] Abstract

Utility of Single Cell Genomics in Diagnostic Evaluation of Prostate Cancer

Investigators demonstrated that sparse DNA sequencing of single cell nuclei from prostate core biopsies is a rich source of quantitative parameters for evaluating neoplastic growth and aggressiveness. [Cancer Res] Abstract

ELL2 Regulates DNA Non-Homologous End Joining (NHEJ) Repair in Prostate Cancer Cells

Knockdown of ELL2 sensitized prostate cancer cells to DNA damage and overexpression of ELL2 protected prostate cancer cells from DNA damage. [Cancer Lett] Abstract

Synergistic Cytotoxicity of a Prostate Cancer-Specific Immunotoxin in Combination with the BH3 Mimetic ABT-737

Researchers showed that the combination therapy of immunotoxin plus ABT-737 is a promising approach for the future treatment of advanced prostate cancer to improve therapeutic efficacy and to reduce adverse side effects. [Cancer Immunol Immunother] Abstract

Doxycycline Induces Apoptosis via ER Stress Selectively to Cells with a Cancer Stem Cell-Like Properties: Importance of Stem Cell Plasticity

Scientists showed that under sphere-forming assay conditions, prostate cancer cells acquired cancer stem cell (CSC)-like properties: promoted mitochondrial respiratory chain activity, expression of characteristic CSC markers and resistance to anticancer agents. [Oncogenesis] Full Article

GOLM1 Promotes Prostate Cancer Progression through Activating PI3K-AKT-mTOR Signaling

GOLM1 expression was up-regulated in prostate cancer (PCa) of all stages and grades. GOLM1 promoted proliferation, migration and invasion, and inhibited apoptosis in PCa cell lines and xenograft mice models. [Prostate] Abstract

Cisplatin or LA-12 Enhance Killing Effects of TRAIL in Prostate Cancer Cells through Bid-Dependent Stimulation of Mitochondrial Apoptotic Pathway but Not Caspase-10

Scientists demonstrated a notable ability of cisplatin or LA-12 to enhance the sensitivity of several human prostate cancer cell lines to TRAIL-induced cell death via an engagement of mitochondrial apoptotic pathway. [PLoS One] Full Article

Regulation of HMGB3 by Antitumor miR-205-5p Inhibits Cancer Cell Aggressiveness and Is Involved in Prostate Cancer Pathogenesis

Investigators identified oncogenic genes and pathways in prostate cancer cells that were regulated by antitumor miR-205-5p. Genome-wide gene expression analyses and in silico miRNA database searches showed that 37 genes were putative targets of miR-205-5p regulation. [J Hum Genet] Abstract

Trichothecenes: Immunomodulatory Effects, Mechanisms, and Anti-Cancer Potential

The authors summarize the data on the immunomodulatory effects of trichothecenes and discuss recent studies that shed light on the underlying cellular and molecular mechanisms. They show how trichothecene bioactivities can be exploited to generate therapies against pathogens and cancer. [Arch Toxicol] Abstract

Visit our reviews page to see a complete list of reviews in the prostate cell research field.

Genomic Health and Cleveland Diagnostics Announce Strategic Collaboration to Develop and Commercialize New Prostate Cancer Tests

Genomic Health, Inc. and Cleveland Diagnostics, Inc. announced an exclusive licensing agreement to develop and commercialize new prostate cancer tests based on Cleveland Diagnostics’ IsoPSA^™ reagents and technology. [Genomic Health, Inc.] Press Release

Phase III Trial of Radium-223 Dichloride in Combination with Abiraterone Acetate and Prednisone/Prednisolone for Patients with Metastatic Castration-Resistant Prostate Cancer Unblinded Early

Bayer announced that an Independent Data Monitoring Committee has recommended to unblind a Phase III trial of radium-223 dichloride (radium-223) in combination with abiraterone acetate and prednisone/prednisolone in prostate cancer. [Bayer] Press Release

Health Agency Reveals Scourge of Fake Drugs in Developing World

One in ten medicines in developing countries is fake or substandard, data from the World Health Organization suggest. Malaria drugs and antibiotics are among the most commonly reported, the agency found. But the problem extends to a variety of medications, including those for cancer, heart disease and HIV, as well as contraceptives and painkillers. [Nature News] Editorial

China to Roll Back Regulations for Traditional Medicine Despite Safety Concerns

Support for traditional medicine in China goes right to the top. President Xi Jinping has called this type of medicine a “gem” of the country’s scientific heritage and promised to give alternative therapies and Western drugs equal government support. The country is taking dramatic steps to promote these cures even as researchers raise concerns about such treatments. [Nature News] Editorial

United States Bans Most Government Scientists from Travel to Cuba

To celebrate its 80^th anniversary, the Pedro Kourí Institute of Tropical Medicine (IPK) is throwing a birthday bash: a conference that several U.S. collaborators were planning to attend. All but one has backed out, says IPK virologist María Guadalupe Guzmán. Some, she says, were unsettled by recent claims that U.S. diplomats in Cuba suffered what the Department of State has described as “health attacks.” [ScienceInsider] Editorial

NEW World Vaccine Congress Washington 2018
April 3-5, 2018
Washington, D.C., United States

Visit our events page to see a complete list of events in the community.

NEW Postdoctoral Fellowship – Prostate Cancer (Duke University Medical Center)

PhD Studentship – Prostate Cancer (CRUK Manchester Institute)

Postdoctoral Positions – Cancer Biology (University of Pennsylvania)

Assistant Professor – Prostate Cancer (University of Illinois)

PhD Student Position – Prostate Cancer (Bellvitge Biomedical Research Institute)

Postdoctoral Position – Prostate Cancer (University of Minnesota)

Faculty Position – Cancer Research (Duke University)

Postdoctoral Position – Drug Discovery for Advanced Prostate Cancer (Lerner Research Institute)

Postdoctoral Position – Cancer Biology (The Henry Ford Health System)

Postdoctoral Position – Prostate Cancer (Baylor College of Medicine)

Postdoctoral Position – Prostate Related Diseases (Baylor College of Medicine)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here.